NEWS & PERSPECTIVE
The 2026 Second Universal Definition of Heart Failure updates diagnostic criteria and disease classifications. Shifting away from rigid ejection fraction cutoffs, it simplifies phenotypes into reduced, preserved, and improved categories. It also introduces universal pathogenic causes, formalizes dynamic trajectories like remission and recovery, and addresses diagnostic mimics to standardize global care.
Ectopic fat accumulation in the pancreas is increasingly recognized for its adverse metabolic consequences, including insulin resistance and diabetes.1-3 While early research established clear associations between fatty pancreas and cardiovascular-kidney-metabolic (CKM) risks, heterogeneous diagnostic criteria historically limited clinical applicability.3,4 A recent study validated the 2026 international consensus magnetic resonance imaging (MRI) thresholds, demonstrating that consensus-defined fatty pancreas is independently associated with incident type 2 diabetes (T2D), chronic kidney disease (CKD), and major adverse cardiovascular events (MACE).3 These results firmly position fatty pancreas as a significant component of the CKM continuum.3
Early foundational research laid the groundwork for understanding this phenomenon.3,4 A study in Hong Kong reported a 16.1% population prevalence of fatty pancreas, noting that individuals with concurrent fatty liver exhibited the highest levels of insulin resistance.2 A prospective cohort study demonstrated that fatty pancreas is an independent risk factor for the subsequent development of diabetes mellitus.1 Over a decade of follow-up, individuals with pancreatic fat exceeding 10.4% had a 1.81 times higher risk of developing diabetes, with each percentage increase raising the risk by 7%.1 Despite this growing body of evidence, previous investigations consistently relied on empirically derived or study-specific diagnostic thresholds, creating heterogeneity that complicated the clinical translation of the findings.3,4
To address this gap, a 2026 international multi-society consensus established standardized magnetic resonance imaging-derived proton density fat fraction thresholds for diagnosing and categorizing fatty pancreas.3 The recent study sought to validate these consensus-based thresholds at the population level by investigating their association with prevalent and incident T2D, CKD, and MACE.3 The study analyzed data from 19,255 participants of European ancestry drawn from the United Kingdom (UK) Biobank imaging sub-study.3 Participants were categorized according to the newly established proton density fat fraction thresholds: normal was defined as less than 6%, mild fatty pancreas as 6% to <16%, and moderate-to-severe fatty pancreas as ≥16%.3
The results of the study demonstrated a graded association between fatty pancreas and T2D.3
Moderate-to-severe fatty pancreas was associated with triple odds of T2D prevalence (adjusted odds ratio [aOR]=3.25; p<0.001), with a similar association observed between mild fatty pancreas and prevalent T2D (aOR=2.37; p<0.001).3 Excluding participants with T2D at or before MRI, higher risk for incident T2D was linked with moderate-to-severe fatty pancreas (adjusted hazard ratio [aHR]=2.72; p<0.001), and mild fatty pancreas (aHR=2.19; p<0.001).3 Each 5% increase in pancreatic proton density fat fraction (PDFF) was linked to higher prevalence (aOR=1.16; p<0.001) and incidence (aHR=1.17; p<0.001).3
In addition to glycemic outcomes, the study revealed critical insights into renal and cardiovascular risks.3 Moderate-to-severe fatty pancreas was linked to a higher incidence of CKD (aHR=1.82; p<0.001), with each 5% increase in pancreatic PDFF linked to a higher risk (aHR=1.11; p<0.001) of CKD.3 It also had a modest association with incident MACE.3 Mild fatty pancreas was associated with an increased risk of incident MACE (aHR=1.29; p=0.013), with a similar risk observed for moderate-to-severe fatty pancreas (aHR=1.30; p=0.034).3 However, the overall cardiovascular associations appeared more modest than the renal and diabetic risks, whereas continuous PDFF increases were not statistically significantly associated with MACE risk (aHR=1.02 per 5% increase; p=0.323).3
By confirming that standardized categories of pancreatic fat independently predict incident T2D, CKD, and MACE, these findings position fatty pancreas within the broader CKM continuum and suggest that pancreatic fat quantification could complement integrated cardiometabolic risk stratification in clinical settings.3 Future research is needed to evaluate whether targeted lifestyle or pharmacologic interventions, such as weight loss or incretin-based therapies, can reduce pancreatic fat and modify associated clinical risks.3 Additionally, validation of these consensus thresholds across more ancestrally diverse populations will be essential prior to widespread clinical implementation.3
